Anti-CD20 antibody therapy for B-cell lymphomas

New England Journal of Medicine

Volumn 366, Issue 21, 2012, Pages 2008-2016

  Maloney, David G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENDAMUSTINE; CD20 ANTIBODY; CD200 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GROWTH FACTOR; LACTATE DEHYDROGENASE; MITOXANTRONE; OBINUTUZUMAB; OFATUMUMAB; PREDNISONE; RITUXIMAB; VINCRISTINE;

ACUTE CORONARY SYNDROME; ANGIONEUROTIC EDEMA; ARTICLE; B LYMPHOCYTE; BACTERIAL INFECTION; BIOPSY TECHNIQUE; BONE MARROW BIOPSY; BRONCHOSPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILL; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG COST; DRUG EFFICACY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG MECHANISM; FEBRILE NEUTROPENIA; FLOW CYTOMETRY; FOLLICULAR LYMPHOMA; HEART ARRHYTHMIA; HEPATITIS B; HISTOPATHOLOGY; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNOHISTOCHEMISTRY; INCISION BIOPSY; INFECTION; INTERSTITIAL LUNG DISEASE; INTESTINE PERFORATION; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LEUKOENCEPHALOPATHY; LYMPH NODE METASTASIS; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MYCOSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; RIGOR; SALVAGE THERAPY; SIDE EFFECT; STEVENS JOHNSON SYNDROME; URTICARIA; VIRUS INFECTION; VIRUS REACTIVATION; WEIGHT REDUCTION;

EID: 84861409254     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMct1114348     Document Type: Article

References (59)

1. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon, France: IARC Press, 2008.
2. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 2011;117:5019-32.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
4. Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med 2010;362:1417-29.
5. Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A 1988;85:208-12.
6. Uchida J, Lee Y, Hasegawa M, et al. Mouse CD20 expression and function. Int Immunol 2004;16:119-29. (Pubitemid 38054633)
7. Beers SA, Chan CH, French RR, Cragg MS, Glennie MJ. CD20 as a target for therapeutic type I and II monoclonal antibodies. Semin Hematol 2010;47:107-14.
8. O'Keefe TL, Williams GT, Davies SL, Neuberger MS. Mice carrying a CD20 gene disruption. Immunogenetics 1998;48: 125-32. (Pubitemid 28302315)
9. Reff ME, Carner K, Chambers KS, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994;83:435-45. (Pubitemid 24030569)
10. Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (rituximab) anti- CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90:2188-95. (Pubitemid 27392702)
11. Wierda WG, Kipps TJ, Mayer J, et al. Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia. J Clin Oncol 2010;28:1749-55. [Erratum, J Clin Oncol 2010;28:3670.]
12. Zelenetz AD. A clinical and scientific overview of tositumomab and iodine I-131 tositumomab. Semin Oncol 2003;30: Suppl 4:22-30. (Pubitemid 36505464)
13. Robak T. GA-101, a third-generation, humanized and glyco-engineered anti- CD20 mAb for the treatment of B-cell lymphoid malignancies. Curr Opin Investig Drugs 2009;10:588-96.
14. McLaughlin P, Grillo-López AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33. (Pubitemid 28363048)
15. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-32. (Pubitemid 28446681)
16. Czuczman MS. CHOP plus rituximab chemoimmunotherapy of indolent B-cell lymphoma. Semin Oncol 1999;26:88-96. (Pubitemid 29523416)
17. Coiffier B, Lepage E, Brière J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-42. (Pubitemid 34438862)
18. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab- CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010;116:2040-5.
19. Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379-91.
20. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9:105-16.
21. Ohmachi K, Tobinai K, Kobayashi Y, et al. Phase III trial of CHOP-21 versus CHOP-14 for aggressive non-Hodgkin's lymphoma: final results of the Japan Clinical Oncology Group Study, JCOG 9809. Ann Oncol 2011;22:1382-91.
22. Marcus R, Imrie K, Belch A, et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105:1417-23. (Pubitemid 40223656)
23. Hiddemann W, Kneba M, Dreyling M, et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced- stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005;106:3725-32. (Pubitemid 41742196)
24. Schulz H, Bohlius JF, Trelle S, et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. J Natl Cancer Inst 2007;99:706-14. (Pubitemid 47078732)
25. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011;377: 42-51. [Erratum, Lancet 2011;377:1154.]
26. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non- Hodgkin's lymphoma. N Engl J Med 1993; 329:987-94.
27. Ziepert M, Hasenclever D, Kuhnt E, et al. Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era. J Clin Oncol 2010;28:2373-80.
28. Persky DO, Unger JM, Spier CM, et al. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008;26:2258-63.
29. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24:3187-205. (Pubitemid 46638957)
30. Witzens-Harig M, Benner A, Rieger M, et al. Rituximab maintenance therapy in diffuse large B-cell lymphoma in a multicenter prospective randomised phase II study. Blood 2011;118:3700. abstract.
31. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-7. (Pubitemid 46638950)
32. Colombat P, Salles G, Brousse N, et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 2001;97:101-6. (Pubitemid 32061248)
33. Martinelli G, Schmitz SF, Utiger U, et al. Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35/98. J Clin Oncol 2010;28: 4480-4.
34. Ghielmini M, Schmitz SF, Cogliatti S, et al. Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). J Clin Oncol 2005;23:705-11. (Pubitemid 46224169)
35. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood 2006;108:3295-301. (Pubitemid 44794222)
36. van Oers MH, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment of relapsed/resistant follicular non- Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 2010; 28:2853-8.
37. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma. J Clin Oncol 2008; 26:5156-64.
38. Press OW, Unger JM, Braziel RM, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol 2006; 24:4143-9. (Pubitemid 46622291)
39. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer 2005;103:1644-51. (Pubitemid 40490025)
40. Knight C, Hind D, Brewer N, Abbott V. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma: systematic review and economic evaluation. Health Technol Assess 2004;8:1-82.
41. Groot MT, Lugtenburg PJ, Hornberger J, Huijens PC, Uyl-de Groot CA. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in the Netherlands. Eur J Haematol 2005;74:194-202. (Pubitemid 40278488)
42. Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003;63:803-43. (Pubitemid 36432084)
43. Hadjinicolaou AV, Nisar MK, Parfrey H, Chivers ER, Ostör AJ. Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 2012;51:653-62.
44. Brennan PJ, Rodriguez Bouza T, Hsu FI, Sloane DE, Castells MC. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009; 124:1259-66.
45. Kollmar O, Becker S, Schilling MK, Maurer CA. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy. Transplantation 2002;73:669-70. (Pubitemid 34193639)
46. Lowndes S, Darby A, Mead G, Lister A. Stevens-Johnson syndrome after treatment with rituximab. Ann Oncol 2002; 13:1948-50. (Pubitemid 36040785)
47. Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456-73.
48. Lau GK. Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Int 2008;2:152-62. (Pubitemid 351650143)
49. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 2009;113: 4834-40.
50. Wolach O, Bairey O, Lahav M. Late-onset neutropenia after rituximab treatment: case series and comprehensive review of the literature. Medicine (Baltimore) 2010;89:308-18.
51. Weng WK, Negrin RS, Lavori P, Horning SJ. Immunoglobulin G Fc receptor FcgammaRIIIa 158 V/F polymorphism correlates with rituximab-induced neutropenia after autologous transplantation in patients with non-Hodgkin's lymphoma. J Clin Oncol 2010;28:279-84.
52. Li SC, Chen YC, Evens AM, et al. Rituximab-induced late-onset neutropenia in newly diagnosed B-cell lymphoma correlates with Fc receptor FcγRIIIa 158(V/F) polymorphism. Am J Hematol 2010;85: 810-2.
53. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002;346:1937-47. (Pubitemid 34651353)
54. Wilson W, Jung SH, Porcu P, et al. A cancer and leukemia group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica 2011 December 1 (Epub ahead of print).
55. Fang C, Xu W, Li JY. A systematic review and meta-analysis of rituximab-based immunochemotherapy for subtypes of diffuse large B cell lymphoma. Ann Hematol 2010;89:1107-13.
56. Ardeshna KM, Qian W, Smith P, et al. An intergroup randomised trial of rituximab versus a watch and wait strategy in patients with stage II, III, IV, asymptomatic, non-bulky follicular lymphoma (grades 1, 2 and 3a): a preliminary analysis. Blood 2010;116:6. abstract.
57. National Comprehensive Cancer Network. Non-Hodgkin's lymphomas. Clinical practice guidelines in oncology, version 2.2012 (http://www.nccn.org/ professionals/ physician-gls/pdf/nhl.pdf).
58. Tilly H, Dreyling M. Diffuse large B-cell non-Hodgkin's lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21: Suppl 5:v172-v174.
59. Dreyling M, Ghielmini M, Marcus R, Salles G, Vitolo U. Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2011;22:Suppl 6:vi59-vi63.